Tags

Type your tag names separated by a space and hit enter

The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
Thromb Haemost. 2005 Jan; 93(1):92-6.TH

Abstract

High levels of plasminogen activator inhibitor type 1 (PAI-1) have been implicated as a risk factor for cardiovascular disease, but its precise role remains controversial. The 4G allele of the PAI-1 4G/5G promoter polymorphism is associated with higher levels of PAI-1. We studied the relationship between ischemic stroke and the PAI-1 4G/5G polymorphism and PAI-1 antigen levels. We performed a case-control study among patients aged 18-75 years with first ischemic stroke, confirmed by CT. All patients were screened for cardiovascular risk factors, cardiac disorders and large vessel disease. We excluded patients with a definite non-atherosclerotic cause of the stroke and patients using oral anticoagulants. Population-controls were age -and sex-matched, without a history of stroke, and of the Caucasian race. Venous blood samples were taken for PAI-1 4G/5G polymorphism and PAI-1 level one week after stroke. We included 124 patients and 125 controls. Mean age was 56 yrs (range 18 to 75 yrs). Sixty one patients (50%) and 58 (47%) controls were heterozygous for the PAI-1 4G/5G polymorphism. The homozygous 4G/4G genotype was found in 33 patients (27%) and in 36 controls (29%). The odds ratio of ischemic stroke associated with 4G-carriers versus 5G/5G homozygotes was 1.0 (95% CI: 0.6-1.8). The relative risk of ischemic stroke associated with the level of PAI-1 in the upper quartile was 0.73 (95%CI: 0.4 to 1.4). Neither the PAI-1 4G/5G polymorphism nor the PAI-1 antigen level is a strong risk factor for ischemic stroke.

Authors+Show Affiliations

Erasmus Medical Center Rotterdam, Department of Neurology, PO Box 2040, 3000 CA Rotterdam, The Netherlands. m.vangoor@erasmusmc.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15630497

Citation

van Goor, Mary-Lou, et al. "The Plasminogen Activator Inhibitor (PAI-1) 4G/5G Promoter Polymorphism and PAI-1 Levels in Ischemic Stroke. a Case-control Study." Thrombosis and Haemostasis, vol. 93, no. 1, 2005, pp. 92-6.
van Goor ML, Gómez García E, Leebeek F, et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thromb Haemost. 2005;93(1):92-6.
van Goor, M. L., Gómez García, E., Leebeek, F., Brouwers, G. J., Koudstaal, P., & Dippel, D. (2005). The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. Thrombosis and Haemostasis, 93(1), 92-6.
van Goor ML, et al. The Plasminogen Activator Inhibitor (PAI-1) 4G/5G Promoter Polymorphism and PAI-1 Levels in Ischemic Stroke. a Case-control Study. Thromb Haemost. 2005;93(1):92-6. PubMed PMID: 15630497.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study. AU - van Goor,Mary-Lou, AU - Gómez García,Encarna, AU - Leebeek,Frank, AU - Brouwers,Geert-Jan, AU - Koudstaal,Peter, AU - Dippel,Diederik, PY - 2005/1/5/pubmed PY - 2005/7/6/medline PY - 2005/1/5/entrez SP - 92 EP - 6 JF - Thrombosis and haemostasis JO - Thromb Haemost VL - 93 IS - 1 N2 - High levels of plasminogen activator inhibitor type 1 (PAI-1) have been implicated as a risk factor for cardiovascular disease, but its precise role remains controversial. The 4G allele of the PAI-1 4G/5G promoter polymorphism is associated with higher levels of PAI-1. We studied the relationship between ischemic stroke and the PAI-1 4G/5G polymorphism and PAI-1 antigen levels. We performed a case-control study among patients aged 18-75 years with first ischemic stroke, confirmed by CT. All patients were screened for cardiovascular risk factors, cardiac disorders and large vessel disease. We excluded patients with a definite non-atherosclerotic cause of the stroke and patients using oral anticoagulants. Population-controls were age -and sex-matched, without a history of stroke, and of the Caucasian race. Venous blood samples were taken for PAI-1 4G/5G polymorphism and PAI-1 level one week after stroke. We included 124 patients and 125 controls. Mean age was 56 yrs (range 18 to 75 yrs). Sixty one patients (50%) and 58 (47%) controls were heterozygous for the PAI-1 4G/5G polymorphism. The homozygous 4G/4G genotype was found in 33 patients (27%) and in 36 controls (29%). The odds ratio of ischemic stroke associated with 4G-carriers versus 5G/5G homozygotes was 1.0 (95% CI: 0.6-1.8). The relative risk of ischemic stroke associated with the level of PAI-1 in the upper quartile was 0.73 (95%CI: 0.4 to 1.4). Neither the PAI-1 4G/5G polymorphism nor the PAI-1 antigen level is a strong risk factor for ischemic stroke. SN - 0340-6245 UR - https://www.unboundmedicine.com/medline/citation/15630497/The_plasminogen_activator_inhibitor__PAI_1__4G/5G_promoter_polymorphism_and_PAI_1_levels_in_ischemic_stroke__A_case_control_study_ L2 - https://www.thieme-connect.com/DOI/DOI?10.1160/TH04-09-0560 DB - PRIME DP - Unbound Medicine ER -